Back to Research Hub
Travere Therapeutics, Inc.
TVTX
$65.67-1.85 (-2.74%)
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II).
StreetsValue research for Travere Therapeutics, Inc. (TVTX)
Members get the full report for Travere Therapeutics, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.